TET2 and myeloproliferative neoplasm: In contrast, MDS/MPN-RS-T patients demonstrated much less heterogeneity, with the majority of recurrent mutations involving SF3B1 (9/12; 75%), JAK2 (8/12; 66.7%), and TET2 (5/12; 41.7%).